Myelodysplastic Syndrome malady

MedlinePlus: Your bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. it contains immature cells, called stem cells. the stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting. if you have a myelodysplastic syndrome, the stem cells do not mature into healthy blood cells. this leaves less room for healthy cells, which can lead to infection, anemia, or easy bleeding. myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. if you have symptoms, they may include shortness of breath weakness or feeling tired skin that is paler than usual easy bruising or bleeding pinpoint spots under the skin caused by bleeding fever or frequent infections myelodysplastic syndromes are rare. people at higher risk are over 60, have had chemotherapy or radiation therapy, or have been exposed to certain chemicals. treatment options include transfusions, drug therapy, chemotherapy, and blood or bone marrow stem cell transplants. nih national cancer institute²³

MalaCards: Myelodysplastic Syndrome, also known as myelodysplastic syndromes, is related to leukemia and myeloid leukemia. An important gene associated with Myelodysplastic Syndrome is MLF1 (myeloid leukemia factor 1), and among its related pathways are Hematopoietic cell lineage and Apoptosis Signaling Pathways. The compounds lipid and retinoic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and liver, and related mouse phenotypes are hematopoietic system and immune system.

NIH Rare Diseases: Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.³⁰

Wikipedia: The myelodysplastic syndromes (MDS, formerly known as preleukemia) are a diverse collection of...⁴⁴ more...

myelodysplastic syndrome 7 33 myelodysplastic syndromes 30 17 32 23

dysmyelopoietic syndromes 43 mds 30

Diseases related to myelodysplastic syndrome by text searches and GeneDecks gene sharing:

(show top 50)    (show all 905)

id	Related Disease	Score	Top Affiliating Genes
1	leukemia	50.3	PIGA, PIAS4, PIK3CG, KLF5, NCAM1, NCL
2	myeloid leukemia	49.3	PIAS4, PIK3CG, KLF5, NCAM1, NCL, NCOA2
3	acute leukemia	41.6	NCAM1, NCL, NCOA2, KIT, KITLG, RB1
4	acute myeloid leukemia	39.3	KIT, CEBPA, MLF1, FLT3, NUP214, NSD1
5	anemia	39.2	PIGA, NCAM1, KIT, KITLG, PCNA, RB1
6	myelomonocytic leukemia	38.6	KIR3DL1, RB1, MYC, MYB, RARA, RAN
7	myeloproliferative disorder	38.1	KIT, KITLG, RAP1A, RAN, KDR, MPL
8	acute lymphoblastic leukemia	37.4	KIT, KITLG, KIR3DL1, BTK, RB1, SELL
9	chronic myelomonocytic leukemia	36.6	RB1, RAN, BIRC5, KAT6A, MPO, JAK2
10	aplastic anemia	35.7	PIGA, KITLG, VEGFA, MPL, CD59, CD40LG
11	hematopoiesis	35.2	PIGA, PIK3CG, KIT, KITLG, PCNA, RB1
12	juvenile myelomonocytic leukemia	34.4	KIR3DL1, RARA, JAK2, IRF1, FLT3, ARHGAP26
13	myeloid malignancy	34.1	KIT, MPL, JAK2, CD40, MLL, MLL5
14	myelofibrosis	34.0	BMP6, JAK2, CD177, FGF2, THPO, EPO
15	wilms tumor	33.5	NCAM1, PCNA, VHL, VEGFA, VDR, MYC
16	acute promyelocytic leukemia	33.4	PIK3CG, NCAM1, MYC, RARA, BCL2, LEPR
17	neutropenia	33.2	KITLG, BTK, BIRC5, BCL2, LEF1, XRCC3
18	hemoglobinuria	33.1	PIGA, SELL, LBR, CD59, CD55, ANXA5
19	breast cancer	33.0	RAD51, CHEK2, BARD1, XRCC3, ATM, HMMR
20	hodgkin's lymphoma	32.9	PIK3CG, BMI1, BIRC2, BIRC3, BCL2, BCL6
21	alpha thalassemia	32.8	ATRX, ARHGAP26, CREBBP, WT1, HBG1, HFE
22	lymphoblastic leukemia	32.5	PIK3CG, KLF5, NCAM1, KIT, KITLG, KIR3DL1
23	myeloma	32.5	PIK3CG, NCAM1, PDE4A, KIT, KITLG, PCNA
24	lymphocytic leukemia	32.2	PIK3CG, NCAM1, NCL, PDE4A, KIT, KITLG
25	chronic lymphocytic leukemia	31.7	PDE4A, SELL, MYB, BIRC2, BIRC3, BIRC5
26	paroxysmal nocturnal hemoglobinuria	31.7	PIGA, SELL, CD59, CD55, PLAUR, ACHE
27	sarcoma	31.7	PIAS4, PIK3CG, NCAM1, PDE4A, KIT, KITLG
28	mastocytosis	31.6	KIT, KITLG, RARA, BGLAP, BCL2, MPO
29	prostatitis	31.2	PIAS4, PIK3CG, KLF5, NCAM1, NCL, NCOA2
30	thalassemia	31.1	KLF11, KIR3DL1, SERPINC1, VDR, MYB, BGLAP
31	ovarian cancer	31.0	RB1, CHEK2, CDKN2C, CDKN2B, CDKN2D, CDKN2A
32	melanoma	30.9	PIK3CG, KLF5, NCAM1, NCL, NCOA2, PDE4A
33	acute myelomonocytic leukemia	30.9	MPO, MLL, CBFB, ETV6, CREBBP, DNTT
34	stem cell leukemia	30.7	KIT, MPO, FLT3LG, FLT3, FGFR1, TRD@
35	pyoderma	30.5	BTK, CD40LG, CD55, MEFV, IL6, IL8
36	thrombocytopenia	30.3	PIGA, NCAM1, KITLG, SELL, SERPINC1, MYB
37	muscular dystrophy	30.0	PIAS4, NCAM1, VEGFA, KDR, BCL2, CFLAR
38	hemochromatosis	29.8	BMP6, B2M, MPO, INS, IL6, GPT
39	fanconi's anemia	29.7	KITLG, PCNA, RB1, BMP6, RAD51, LIG4
40	hepatitis	29.7	GZMB, ARG1, IL2RB, FASLG, FAS, GPT
41	multiple myeloma	29.7	PIK3CG, NCAM1, KIT, KITLG, PCNA, RB1
42	splenomegaly	29.6	VEGFA, ATM, MPL, JAK2, FASLG, FAS
43	li-fraumeni syndrome	29.3	RB1, BCL2, CHEK2, BAX, ATM, CDKN2A
44	t-cell leukemia	29.3	PIK3CG, MYC, MYB, BIRC3, BIRC5, BCL2
45	monocytic leukemia	29.3	NCOA2, VEGFA, MYC, BMP6, RARA, BIRC5
46	neurofibromatosis	29.3	KIT, KITLG, VHL, VEGFA, MYC, RAP1A
47	thrombocytosis	29.1	KITLG, SERPINC1, VEGFA, CEBPB, MPL, JAK2
48	immunodeficiency	28.7	KIR3DL1, BTK, SELL, BMP6, PARP1, CFLAR
49	behcet's disease	28.6	KIR3DL1, SELL, LBR, MICB, MEFV, IL8
50	pulmonary alveolar proteinosis	28.6	VDR, MMP9, IL1B, IL3, IL8, CASP3

Approved drugs:

Drug clinical trials:

Cell-based therapeutics:

MalaCards organs/tissues related to myelodysplastic syndrome:

²²

MGI Mouse Phenotypes related to myelodysplastic syndrome:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system phenotype	MP:0005397	18.3	PIGA, PIAS4, KIT, PCNA, BTK, SERPINB1
2	immune system phenotype	MP:0005387	17.4	PIAS4, KLF5, NCOA2, PDE4A, KIT, BTK
3	mortality/aging	MP:0010768	15.8	PIGA, PIAS4, KLF5, NCAM1, KITLG, BTK
4	cellular phenotype	MP:0005384	15.2	PIGA, PIK3CG, KLF5, NCAM1, KIT, KITLG
5	homeostasis/metabolism phenotype	MP:0005376	15.1	PIK3CG, KLF5, KIT, KITLG, BTK, RB1
6	normal phenotype	MP:0002873	14.5	KLF11, KLF5, VHL, VEGFA, MYC, MYB
7	embryogenesis phenotype	MP:0005380	13.9	PIGA, KLF5, NCOA2, KIT, SERPINC1, VHL
8	integument phenotype	MP:0010771	13.6	PIGA, PIK3CG, NCOA2, KIT, KITLG, BTK
9	growth/size phenotype	MP:0005378	13.5	PIGA, PIK3CG, KLF5, NCOA2, KIT, KITLG
10	nervous system phenotype	MP:0003631	12.9	PIGA, PDE4A, KIT, KITLG, RB1, SERPINC1
11	craniofacial phenotype	MP:0005382	12.6	PIGA, KIT, KITLG, BMI1, LIG4, LEF1
12	limbs/digits/tail phenotype	MP:0005371	12.2	KIT, KITLG, BTK, RB1, VHL, VEGFA
13	reproductive system phenotype	MP:0005389	12.2	PIGA, NCOA2, VHL, VEGFA, VDR, RARA
14	endocrine/exocrine gland phenotype	MP:0005379	12.1	KLF5, NCOA2, SELL, PAIP2, XRCC4, CDKN2C
15	respiratory system phenotype	MP:0005388	11.9	KLF5, SELL, SERPINB1, BCL6, LEPR, CDKN2D
16	renal/urinary system phenotype	MP:0005367	11.6	KIT, VHL, RARA, BCL2, LEPR, BAX
17	digestive/alimentary phenotype	MP:0005381	11.6	PIGA, KLF5, KIT, KITLG, BTK, RB1
18	liver/biliary system phenotype	MP:0005370	11.4	KIT, SERPINC1, VHL, VEGFA, MYB, LIG4
19	tumorigenesis	MP:0002006	11.2	PIGA, KLF11, KIT, KITLG, BTK, RB1
20	hearing/vestibular/ear phenotype	MP:0005377	10.6	KIT, KITLG, RB1, VDR, MYC, RARA
21	skeleton phenotype	MP:0005390	10.5	PIGA, PIK3CG, KIT, KITLG, RB1, VHL
22	cardiovascular system phenotype	MP:0005385	10.5	PIK3CG, KLF5, PDE4A, KIT, KITLG, RB1
23	behavior/neurological phenotype	MP:0005386	10.4	PIGA, NCAM1, NCOA2, KIT, RB1, BMI1
24	pigmentation phenotype	MP:0001186	10.2	KIT, KITLG, RB1, SERPINC1, MYC, USF2
25	no phenotypic analysis	MP:0003012	10.2	NCOA2, PCNA, RB1, VEGFA, MYC, PAIP2
26	other phenotype	MP:0005395	10.1	RARA, KDR, LEPR, JAK2, CDKN2A, CD40LG
27	vision/eye phenotype	MP:0005391	9.3	NCAM1, KIT, KITLG, RB1, SERPINC1, VEGFA
28	adipose tissue phenotype	MP:0005375	9.3	RB1, MYC, BCL2, LEF1, LEPR, LBR
29	muscle phenotype	MP:0005369	8.9	PIK3CG, KLF5, KIT, RB1, VHL, VEGFA

Articles related to myelodysplastic syndrome:

(show top 50)    (show all 841)

id	Title	Authors	Year	Affiliating Genes
1	Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. (19407318)	Gaymes T.J.... Mufti G.J.	2009	PARP1
2	Reduced CD38 expression on CD34+ cells as a diagnosti c test in myelodysplastic syndromes. (19644143)	Goardon N.... Freeman S.	2009	CD34, CD38
3	Relationship between expression of mutant type glutat hione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome. (19843381)	Maeda Y.... Kanamaru A.	2009	GSTT1
4	An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. (19152429)	Mundle S.... Moyo V.	2009	CSF2
5	Rearrangements and amplification of IER3 (IEX-1) repr esent a novel and recurrent molecular abnormality in myelodysplastic syndromes. (19773435)	Steensma D.P.... Ketterling R.P.	2009	IER3
6	Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia (18241656)	Tian S.L.... He W.	2008	IL3
7	Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome (18247301)	Yao D.M.... Chen Z.X.	2008	FHIT
8	Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion. (18305556)	Stavropoulou C.... Makropoulos V.	2008	GSTT1, GSTM1
9	GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes. (17570514)	Maratheftis C.I.... Voulgarelis M.	2007	GATA1
10	The correlation study of PTEN gene expression and Ak t phosphorylation in myelodysplastic syndrome (18072631)	Chen B.G.... Tao D.D.	2007	AKT1, PTEN
11	Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13). (16757412)	Janssen H.... Cools J.	2006	GOT1, ETV6
12	High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. (16681638)	Mannone L.... Fenaux P.	2006	CSF3
13	NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. (16223780)	Braun T.... Kroemer G.	2006	AIFM1, ENDOG
14	Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. (16787503)	Georgiou G.... Panayiotidis P.	2006	FLT3
15	A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. (16480427)	Costa D.B.... Higgs D.R.	2006	ATRX
16	Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. (16341237)	Issa J.P.	2005	DNMT1
17	Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array. (15611930)	MartA-nez-RamA-rez A.... BenA-tez J.	2005	BCL2, BCL6
18	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. (15863204)	Giles F.J.... Estey E.	2005	IL11
19	Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. (16104874)	Papageorgiou S.G.... Economopoulos T.	2005	CDKN1C, CDKN2C
20	Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome. (16146847)	Takaku T.... Ohyashiki K.	2005	CD8A
21	The geldanamycin derivative 17-AAG decreases VEGF sec retion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone m arrow stromal cells. (15804996)	Hawkins L.M.... Narendran A.	2005	VEGFA
22	Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. (15681838)	Campioni D.... Zauli G.	2005	TNFSF10
23	Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. (15481442)	Li X.... Deeg H.J.	2004	ANXA5
24	Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report. (14962248)	Clavio M.... Rodriguez G.	2004	EPO
25	Expression and significance of apoptosis protein inhibitor survivin and XIAP, in patients with myelodysplastic syndromes and in the cell line MUTZ-1 (14990073)	Cai Z.... Wuchter C.	2004	BIRC5, XIAP
26	Mutations in PTPN11 are uncommon in adult myelodysplastic syndromes and acute myeloid leukaemia. (15009076)	Johan M.F.... Reilly J.T.	2004	PTPN11
27	Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. (12717436)	Tartaglia M.... Gelb B.D.	2003	PTPN11
28	Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. (12965081)	Saberwal G.... Mundle S.D.	2003	CCND1, E2F1
29	Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia (12971856)	Yang J.K.... Cao J.N.	2003	WT1
30	No significant correlation exists between nitric oxide production and apoptosis in myelodysplastic syndromes. (12486325)	Choi J.W.	2003	NOS2
31	Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. (12668650)	Josting A.... Diehl V.	2003	CSF3
32	In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. (11861273)	Claessens Y.E.... Fontenay-Roupie M.	2002	FAS, KITLG
33	High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. (11699417)	Verstovsek S.... Albitar M.	2001	TIE1
34	Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome. (11021751)	Matsumoto N.... Fukuhara S.	2000	MLF1
35	The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. (11090080)	Parker J.E.... Pagliuca A.	2000	ANXA5, BOK
36	Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. (11039660)	Cazzola M.	2000	CSF3
37	Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. (10692673)	Kurotaki H.... Yagihashi S.	2000	TP53, BCL2
38	Unusual clinical presentation in a patient with myelodysplastic syndrome, with subsequent hematological remission and suppression of the malignant clone following treatment with cyclosporine A, erythropoietin and granulocyte colony-stimulating factor. (10374866)	Samuelsson J.... LAorfars G.	1999	CSF3, EPO
39	Mutation of the WT1 gene in myelodysplastic syndrome and acute myeloid leukaemia post myelodysplastic syndrome. (10354161)	Mori N.... Mizoguchi H.	1999	WT1
40	Haematopoietic growth factors in the treatment of myelodysplastic syndromes. (10101210)	Cazzola M.	1999	CSF3
41	A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. (9886322)		1998	EPO
42	Is apoptosis a massive process in myelodysplastic syndromes? (8904894)	Lepelley P.... Fenaux P.	1996	DNTT
43	MDR1 gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome. (7915092)	ZAPchbauer S.... Pirker R.	1994	ABCB1
44	p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. (8053492)	Kitagawa M.... Kamiyama R.	1994	TP53
45	Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment. (8485205)	Yoshida Y.... Okuma M.	1993	EPO
46	Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. (8350630)	Preudhomme C.... Fenaux P.	1993	MDM2
47	Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin (8235952)	RodrA-guez J.N.... MuA+iz R.	1993	EPO
48	Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b. (1988303)	Aul C.... Schneider W.	1991	IFNA1
49	Transforming genes and chromosome aberrations in ther apy-related leukemia and myelodysplastic syndrome. (1854883)	Inokuchi K.... Nomura T.	1991	GGT1
50	The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes. (2276114)	Greenberg P.L.... Nagler A.	1990	CSF3

Genes related to myelodysplastic syndrome according to GeneCards:

(show top 50)    (show all 402)

id	Symbol	Description	Score	GeneCards Section Context
1	MLF1	myeloid leukemia factor 1	11.1	Publications, Summaries, Functions
2	PRDM16	PR domain containing 16	11.1	Publications, Summaries
3	PURB	purine-rich element binding protein B	11.0	UniProt Related, Publications, Summaries
4	ASXL1	additional sex combs like 1 (Drosophila)	11.0	Summaries, Publications
5	PURA	purine-rich element binding protein A	11.0	Summaries, Publications
6	ACSL6	acyl-CoA synthetase long-chain family member 6	11.0	Summaries, Publications
7	MDS2	myelodysplastic syndrome 2 translocation associated	11.0	Proteins, Aliases & Descriptions, Publications, Transcripts
8	POGLUT1	protein O-glucosyltransferase 1	11.0	Aliases & Descriptions, Orthologs
9	RPL22	ribosomal protein L22	11.0	Summaries
10	NUP214	nucleoporin 214kDa	11.0	Summaries
11	TEC	tec protein tyrosine kinase	11.0	Summaries
12	IRF1	interferon regulatory factor 1	11.0	Publications, UniProt Related
13	CSF3	colony stimulating factor 3 (granulocyte)	11.0	Publications
14	MLL	myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)	11.0	Publications
15	EPO	erythropoietin	11.0	Publications
16	FTMT	ferritin mitochondrial	11.0	Publications
17	NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog	11.0	Publications
18	MNDA	myeloid cell nuclear differentiation antigen	11.0	Publications
19	HOXA9	homeobox A9	11.0	Publications
20	DLK1	delta-like 1 homolog (Drosophila)	11.0	Publications
21	IL3	interleukin 3 (colony-stimulating factor, multiple)	11.0	Publications
22	MPL	myeloproliferative leukemia virus oncogene	11.0	Publications
23	BOK	BCL2-related ovarian killer	11.0	Publications
24	NUP98	nucleoporin 98kDa	11.0	Functions, Publications
25	CSF3R	colony stimulating factor 3 receptor (granulocyte)	11.0	Publications
26	WT1	Wilms tumor 1	11.0	Functions, Publications
27	GATA2	GATA binding protein 2	11.0	Publications
28	DNTT	deoxynucleotidyltransferase, terminal	11.0	Publications
29	FLT3	fms-related tyrosine kinase 3	11.0	Publications, Functions
30	CSF2	colony stimulating factor 2 (granulocyte-macrophage)	11.0	Publications
31	CD177	CD177 molecule	11.0
32	CDKN2B	cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	11.0	Publications
33	EPOR	erythropoietin receptor	11.0	Publications
34	THPO	thrombopoietin	11.0	Publications
35	SPN	sialophorin	11.0	Publications
36	PIGA	phosphatidylinositol glycan anchor biosynthesis, class A	11.0	Publications
37	CD33	CD33 molecule	11.0	Publications
38	NPM1	nucleophosmin (nucleolar phosphoprotein B23, numatrin)	11.0	Functions, Publications
39	RUNX1	runt-related transcription factor 1	11.0	Publications
40	CD34	CD34 molecule	11.0	Publications
41	TERC	telomerase RNA component	11.0	Publications
42	ANG	angiogenin, ribonuclease, RNase A family, 5	11.0	Publications
43	BMI1	BMI1 polycomb ring finger oncogene	11.0	Publications
44	CDKN2C	cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)	11.0	Publications
45	DNMT1	DNA (cytosine-5-)-methyltransferase 1	11.0	Publications
46	CSF1	colony stimulating factor 1 (macrophage)	11.0	Publications
47	CSF1R	colony stimulating factor 1 receptor	11.0	Publications
48	CD59	CD59 molecule, complement regulatory protein	11.0	Publications
49	CDKN1C	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	11.0	Publications
50	ATRX	alpha thalassemia/mental retardation syndrome X-linked	11.0	Publications

Pathways related to myelodysplastic syndrome according to GeneDecks:

(show top 50)    (show all 303)

id	Pathway	Score	Top Affiliating Genes
1	Hematopoietic cell lineage20	11.8	KIT, KITLG, CD33, CD8A, CD59, CD34
2	Apoptosis Signaling Pathways37	11.3	BIRC2, BIRC3, BIRC5, BIRC7, BCL2, BAX
3	Paxillin Interactions36	11.3	KIT, KITLG, KDR, ITGA2B, FLT1, FLT4
4	Acute myeloid leukemia20	11.1	PIK3CG, KIT, MYC, RARA, LEF1, CEBPA
5	Natural killer cell mediated cytotoxicity20	11.0	PIK3CG, KIR3DL1, CD244, GZMB, MICB, FASLG
6	Pancreatic cancer20	10.9	IKBKG
7	eNOS Signaling36	10.9	KIT, KITLG, BMP6, FLT4, FLT3, INSR
8	Jak-STAT signaling pathway20	10.8	PIAS4, PIK3CG, MYC, LEPR, MPL, JAK2
9	IL-6 Pathway36	10.8	BTK, BMP6, BAX, CD80, IL11, IL3
10	Colorectal cancer20	10.7	PIK3CG, LEF1, FOS, TGFB1, TGFBR2
11	Apoptosis and survival_Apoptotic TNF-family pathways41	10.7	BIRC2, BCL2, BAX, XIAP, FASLG, FAS
12	14-3-3 Induced Intracellular Signaling36	10.6	KITLG, FLT1, FLT4, FLT3, INSR, FGF1
13	Development Prolactin receptor signaling10	10.6	MYC, BCL2, CEBPB, JAK2, IRF1, MAPK3
14	Development_Prolactin receptor signaling41	10.6	MYC, BCL2, CEBPB, JAK2, IRF1, MAPK3
15	Apoptosis20	10.4	PIK3CG, BIRC2, BIRC3, BCL2, BAX, XIAP
16	Chronic myeloid leukemia20	10.3	PIK3CG, RB1, MYC, CDKN2A, CDK4, MECOM
17	Apoptosis and survival_TNFR1 signaling pathway41	10.3	BIRC2, BIRC3, BCL2, BAX, XIAP, CFLAR
18	Molecular Mechanisms of Cancer36	10.1	PIK3CG, KITLG, BTK, RB1, MYC, BMP6
19	Activation of PKA through GPCR36	10.0	KIT, KITLG, BMP6, RAP1A, RAP1B, KDR
20	Pathways in cancer20	10.0	PIAS4, PIK3CG, RB1, VEGFA, MYC, RAD51
21	Telomerase Components in Cell Signaling36	9.9	KIT, KITLG, RB1, MYC, BMP6, KDR
22	P2Y Receptor Signaling36	9.8	KIT, MYC, KDR, FOS, FLT1, FLT4
23	Melanoma20	9.7	PIK3CG, RB1, CDKN2A, CDK4, MITF, FGF1
24	PPAR Pathway36	9.7	KIT, KITLG, ITGA2B, FLT1, FLT4, FGF1
25	Glioma20	9.6	PIK3CG, RB1, CDKN2A, CDK4, MDM2, MAPK3
26	Endothelin-1 Signaling Pathway36	9.5	KIT, BTK, MYC, BMP6, CD80, FLT1
27	PAK Pathway36	9.4	KIT, KITLG, BTK, BMP6, KDR, BCL2
28	Nanog in Mammalian ESC Pluripotency36	9.3	KIT, KITLG, BMP6, KDR, FLT1, FLT4
29	p53 Mediated Apoptosis36	9.3	KIT, KITLG, BMP6, KDR, BCL2, CHEK2
30	T cell receptor signaling pathway20	9.3	PIK3CG, CD8A, CD40LG, CDK4, FOS, IL2
31	Osteoclast differentiation20	9.2	PIK3CG, BTK, FOS, MITF, IL1A, IL1B
32	p38 Signaling36	9.1	KIT, KITLG, BTK, BMP6, KDR, BCL2
33	MAPK signaling pathway20	9.1	MYC, RAP1A, RAP1B, FOS, FGF1, FGF2
34	14-3-3 Induced Apoptosis36	9.0	BCL2, FOS, IL1A, IL1B, MAPK3, MAPK14
35	ERK Signaling36	9.0	KIT, KITLG, BTK, MYC, BMP6, RAP1A
36	Prostate cancer20	8.9	PIK3CG, RB1, BCL2, LEF1, INS, FGFR1
37	Pancreatic Adenocarcinoma36	8.9	KIT, KITLG, RB1, BMP6, BIRC5, KDR
38	p70S6K Signaling36	8.8	KIT, KITLG, BMP6, KDR, JAK2, CD19
39	Antioxidant Action of Vitamin-C36	8.8	KIT, KITLG, BTK, BMP6, KDR, BCL2
40	JAK-STAT Pathway36	8.7	KIT, KITLG, BTK, MYC, BMP6, RAN
41	eIF2 Pathway36	8.7	KIT, KITLG, BMP6, FLT4, INS, INSR
42	Estrogen Pathway36	8.7	NCOA2, KIT, KITLG, BMP6, KDR, BCL2
43	DHA Signaling36	8.6	KIT, KITLG, BMP6, KDR, BCL2, BAX
44	MIF Mediated Glucocorticoid Regulation36	8.4	BTK, BMP6, BCL2, BAX, CD80, IL11
45	TGF-Beta Pathway36	8.4	KITLG, BTK, BMP6, KDR, BCL2, BAX
46	Glucocorticoid Receptor Signaling36	8.4	BTK, BMP6, BCL2, BAX, CEBPB, CEBPA
47	MIF Regulation of Innate Immune Cells36	8.4	BTK, BMP6, BCL2, BAX, CD80, FOS
48	Bladder cancer20	8.2	RB1, VEGFA, MYC, CDKN2A, CDK4, MMP2
49	Tuberculosis20	8.0	VDR, BCL2, BAX, CEBPB, JAK2, IL1A
50	MAPK Family Pathway36	7.9	KITLG, BTK, BMP6, KDR, BCL2, BAX

Compounds related to myelodysplastic syndrome according to GeneDecks:

(show top 50)    (show all 448)

id	Compound	Score	Top Affiliating Genes
1	lipid32	13.2	PIK3CG, NCAM1, NCL, PDE4A, KITLG, KIR3DL1
2	retinoic acid32 42 18	14.6	PIK3CG, NCAM1, NCL, NCOA2, PDE4A, KIT
3	glucose32	12.3	PDE4A, KIT, VHL, MT-CO1, XIAP, CFLAR
4	threonine32	12.1	BTK, RAP1A, MPL, CDKN2C, CDKN2B, CDC25C
5	methionine32	12.0	KIT, SERPINA3, MYB, LBR, FOLR1, FN1
6	proline32	11.9	KLF5, BTK, VHL, JAK2, CD80, CDC25C
7	iron32 18	12.8	KITLG, SERPINA3, VHL, MYB, USF2, UQCRFS1
8	progesterone32 42 9 18 9	15.7	NCAM1, NCOA2, PDE4A, KIT, PCNA, RB1
9	dmso32	11.6	KITLG, BMP6, FPR1, INSR, ALOX5, CASP1
10	imatinib32 34 9 9	14.4	PIK3CG, KIT, KITLG, SELL, VEGFA, MYC
11	ionomycin32	11.4	BTK, SERPINA3, RAP1A, CD69, CDK4, CD40
12	estrogen32	11.3	KLF5, NCL, NCOA2, PCNA, SERPINC1, SERPINA3
13	cyclophosphamide32 34 9 9	14.3	PIGA, BCL6, MVP, FLT3LG, TRB@, LTF
14	heparin32 9 18 9	14.2	PIK3CG, NCAM1, NCL, KITLG, SERPINA3, SERPINB1
15	egcg32	11.2	PIK3CG, XIAP, IL1A, MAPK3, MAPK14, DDIT3
16	aspartate32	11.2	PCNA, VDR, BMP6, RARA, B2M, AURKA
17	mitomycin c32	11.2	PCNA, RB1, RAD51, BIRC5, MVP, XRCC3
18	neomycin32	11.1	KITLG, CDKN2A, IL1A, IL3, IL7, ANG
19	butyrate32	11.0	KITLG, PCNA, RB1, VDR, MYC, MYB
20	aspirin32 34 18	13.0	PDE4A, KITLG, PCNA, SELL, SERPINC1, VDR
21	hoechst 3334232	11.0	NCL, KITLG, PCNA, BIRC5, PARP1, BCL2
22	fatty acid32	11.0	MYB, USF2, BCHE, LEPR, MT-CO1, CEBPA
23	wortmannin32 42	11.7	PIK3CG, PDE4A, KITLG, BTK, RAD51, RAP1B
24	roscovitine32	10.7	PIK3CG, PCNA, BIRC5, PARP1, XIAP, MAPK3
25	rituximab32 34 9 9	13.7	BIRC2, BIRC5, BCL2, BCL6, XIAP, CFLAR
26	sp 60012532 42	11.5	PIK3CG, BIRC2, BIRC3, CD40, IKBKB, CASP3
27	bromodeoxyuridine32	10.5	NCAM1, KITLG, PCNA, BTK, RB1, MYC
28	sunitinib32 9 9	12.3	KIT, VHL, VEGFA, KDR, FLT1, FLT4
29	gf 109203x32 42	10.9	PIK3CG, KITLG, BTK, VEGFA, RAP1A, JAK2
30	4-hydroxytamoxifen32	9.9	NCOA2, MYC, PARP1, FASLG, MAPK1, CYP1A1
31	sulindac sulfide32	9.9	PCNA, BMP6, BCL2, BAX, CCND1, CASP3
32	trastuzumab32 34 9 9	12.8	PIK3CG, KIT, BIRC5, KDR, CDK4, MDM2
33	okadaic acid32 42	10.8	NCL, RB1, MYC, MYB, BMP6, BCL2
34	sorafenib32 9 9	11.7	KIT, VHL, VEGFA, BIRC3, KDR, CFLAR
35	leukotriene b432 42 18	11.5	PDE4A, SELL, MPO, MMP9, FPR1, FGR
36	suramin32 9 9	11.4	NCAM1, PCNA, VEGFA, BMP6, KDR, FOS
37	prostacyclin32	9.4	PDE4A, SERPINC1, VEGFA, BMP6, RAP1A, KDR
38	tamoxifen32 34 9 9	12.4	NCOA2, PDE4A, PCNA, SERPINC1, VEGFA, VDR
39	prostaglandin32	9.0	PDE4A, KITLG, MT-CO2, CDK4, CD40, MMP9
40	cytochalasin d32 42	9.9	PIK3CG, KITLG, SELL, JAK2, MMP2, MMP9
41	ribavirin32 34 9 9	11.8	LBR, CD40LG, MMP2, MMP9, IL2, IL3
42	silymarin32	8.5	PCNA, VEGFA, BMP6, BIRC5, PARP1, CDC25C
43	ns 39832 42	9.4	PIK3CG, PCNA, BGLAP, PARP1, FGF2, IL1A
44	thalidomide32 42 9 9	11.3	PDE4A, SELL, VEGFA, BIRC2, BIRC3, BIRC5
45	quercetin32 42 9 18 9	12.1	PIK3CG, BIRC5, PARP1, BCL2, BAX, CDK4
46	pdtc32	7.4	PIK3CG, BIRC3, BIRC5, PARP1, BCL2, XIAP
47	troglitazone32 42 9 9	10.2	PIK3CG, RB1, VDR, BMP6, RARA, BIRC5
48	triptolide32	6.9	VEGFA, BIRC3, PARP1, BCL2, BAX, CD40
49	curcumin32	6.8	PIK3CG, VEGFA, MYC, BIRC2, BIRC3, BIRC5
50	genistein32 9 18 9	9.5	PIK3CG, NCOA2, KITLG, PCNA, BTK, RB1

Cellular components related to myelodysplastic syndrome according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	nucleus	GO:005634	13.6	DIDO1, NF1, NFKB1, NFKBIA, PDGFRA, PDGFRB
2	plasma membrane	GO:005886	13.5	LRRTM2, TFRC, ABCB1, ABCB11, ABCC1, ACHE
3	cytoplasm	GO:005737	13.4	CBL, FLT4, FLT1, IRF1, GZMB, MKI67
4	integral to plasma membrane	GO:005887	12.6	ENPP3, FASLG, IL2RB, FGFR1, INSR, MICB
5	cytosol	GO:005829	11.5	GSTM1, FHIT, INSR, ARG1, ARHGAP26, IRF8
6	nucleoplasm	GO:005654	11.1	NR0B2, NPM1, RRM2B, E2F1, EP300, GATA1
7	external side of plasma membrane	GO:009897	11.0	IL4, ANXA5, FAS, FASLG, IL2RB, ITGA2B
8	cell surface	GO:009986	10.9	SPN, CR1, PLAUR, ABCB1, TGFA, TGFB1
9	nuclear matrix	GO:016363	10.9	MYB, CEBPB, CEBPA, JAK2, MATR3, ALOX5
10	membrane raft	GO:045121	10.5	TRAF2, IKBKB, ANGPT1, FAS, CD55, TNF
11	membrane	GO:016020	10.4	ABCB11, ABCB1, PDGFRB, CTNNB1, HLA-DRB1, IGF1R
12	extracellular region	GO:005576	8.4	IL11, FGFR1, FGF2, FGF1, INS, FLT4
13	extracellular space	GO:005615	7.8	KIT, KITLG, SERPINC1, SERPINB1, VEGFA, INS

Biological processes related to myelodysplastic syndrome according to GeneDecks:

(show top 50)    (show all 66)

id	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of transcription from RNA polymerase II promoter	GO:000122	11.7	PIAS4, KLF11, NCOA2, VHL, VDR, MYC
2	signal transduction	GO:007165	11.6	PDE4A, KIT, KITLG, VDR, RAP1A, RAP1GAP
3	embryonic hemopoiesis	GO:035162	11.6	KIT, KITLG, KDR, KAT6A, MLL, FLT3LG
4	virus-host interaction	GO:019048	11.5	RB1, RAN, KDR, BAX, CFLAR, CEBPA
5	blood coagulation	GO:007596	11.3	PIK3CG, SELL, SERPINC1, VEGFA, MYB, RAP1A
6	peptidyl-tyrosine phosphorylation	GO:018108	11.2	KIT, BTK, KDR, JAK2, FLT1, FLT4
7	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	11.2	BOK, MYC, BCL2L10, BAX, JAK2, CDKN2A
8	induction of apoptosis by extracellular signals	GO:008624	11.2	BTK, VDR, BAX, CFLAR, CD38, FASLG
9	positive regulation of gene expression	GO:010628	11.1	KIT, VEGFA, VDR, LEF1, CD34, PLAUR
10	protein autophosphorylation	GO:046777	11.1	KIT, KDR, CHEK2, AURKA, ATM, JAK2
11	cellular response to hypoxia	GO:071456	11.1	VHL, VEGFA, UBE2D2, MDM2, ICAM1, TP53
12	apoptotic process	GO:006915	11.0	KLF11, BTK, BOK, BIRC2, BIRC3, BIRC5
13	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	11.0	KIT, KDR, JAK2, FLT1, FLT3, INS
14	activation of pro-apoptotic gene products	GO:008633	10.9	MYC, BCL2, BAX, GZMB, FASLG, FAS
15	cytokine-mediated signaling pathway	GO:019221	10.9	NCAM1, KIT, B2M, CEBPA, JAK2, IRF1
16	immune response	GO:006955	10.8	KIR3DL1, BMP6, CEBPB, CD8A, CD1A, IRF8
17	induction of apoptosis	GO:006917	10.8	BOK, BAX, CEBPB, CDKN2C, CDKN2A, IRF1
18	positive regulation of phosphatidylinositol 3-kinase activity	GO:043552	10.8	KIT, FLT1, FLT3, FGF2, FGR, TEK
19	regulation of immune response	GO:050776	10.8	KIR3DL1, SELL, BCL6, B2M, CD8A, CD40LG
20	negative regulation of transcription, DNA-dependent	GO:045892	10.7	PIAS4, RB1, VDR, MYB, RARA, BIRC5
21	innate immune response	GO:045087	10.6	PIK3CG, BTK, BCL2, ATG12, ATG5, CD55
22	positive regulation of I-kappaB kinase/NF-kappaB cascade	GO:043123	10.6	BIRC2, BIRC3, CFLAR, CD40, IL1A, IL1B
23	cell cycle arrest	GO:007050	10.6	RB1, MYC, BARD1, ATM, CDKN2C, CDKN2B
24	organ regeneration	GO:031100	10.6	LEF1, CEBPA, MKI67, ANGPT2, ANGPT1, CCND1
25	positive regulation of cell proliferation	GO:008284	10.6	KLF5, KIT, VEGFA, MYC, RARA, BIRC5
26	positive regulation of apoptotic process	GO:043065	10.5	PIAS4, KLF11, BCL6, BARD1, BAX, ATM
27	positive regulation of cell migration	GO:030335	10.4	VEGFA, KDR, LEF1, JAK2, FLT1, INS
28	response to DNA damage stimulus	GO:006974	10.4	MYC, BCL2, BCL6, CHEK2, BARD1, BAX
29	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	10.2	KITLG, VEGFA, JAK2, CD80, INS, IL11
30	positive regulation of MAP kinase activity	GO:043406	10.2	PIK3CG, KITLG, VEGFA, CD40, FLT1, FLT3
31	positive regulation of angiogenesis	GO:045766	10.2	VEGFA, KDR, CD34, MMP9, FLT1, FGF1
32	induction of apoptosis by intracellular signals	GO:008629	10.1	MYC, BCL2, BAX, XIAP, GZMB, CASP3
33	negative regulation of cell proliferation	GO:008285	10.1	KLF11, VHL, VDR, BCL6, CEBPA, JAK2
34	response to drug	GO:042493	10.1	PDE4A, MYC, BGLAP, BCHE, BCL2, UQCRFS1
35	angiogenesis	GO:001525	10.1	PIK3CG, KLF5, NCL, VEGFA, KDR, MMP2
36	cellular response to mechanical stimulus	GO:071260	9.9	CD40, IRF1, IL1B, FAS, MAPK3, CASP1
37	anti-apoptosis	GO:006916	9.8	VHL, BIRC2, BIRC3, BIRC5, BIRC7, BCL2
38	positive regulation of ERK1 and ERK2 cascade	GO:070374	9.8	KDR, FLT4, FGF2, IL1A, IL1B, ANGPT1
39	platelet activation	GO:030168	9.7	PIK3CG, VEGFA, RAP1A, RAP1B, MPL, CD40LG
40	response to gamma radiation	GO:010332	9.7	MYC, LIG4, BCL2, CHEK2, BAX, XRCC4
41	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.6	NCOA2, RB1, VEGFA, VDR, MYC, MYB
42	negative regulation of apoptotic process	GO:043066	9.6	PIK3CG, VEGFA, MYC, BIRC2, KDR, BCL2
43	positive regulation of protein phosphorylation	GO:001934	9.6	VEGFA, CD40, FLT4, INSR, FGF1, IL1B
44	positive regulation of transcription, DNA-dependent	GO:045893	9.5	KLF5, RB1, VHL, MYC, MYB, RARA
45	activation of MAPK activity	GO:000187	9.3	KIT, FPR1, INSR, FGF2, IL1B, MAPK3
46	response to hypoxia	GO:001666	9.2	VEGFA, BCL2, ATM, MMP9, FLT1, IL1A
47	MAPK cascade	GO:000165	9.0	MYC, INS, FGFR1, IL1B, MAPK3, MAPK1
48	positive regulation of NF-kappaB transcription factor activity	GO:051092	8.8	BTK, CD40, INS, IL1B, IL6, IKBKB
49	positive regulation of sequence-specific DNA binding transcription factor activity	GO:051091	8.5	KIT, JAK2, IL1B, IL4, IL6, AKT1
50	inflammatory response	GO:006954	8.4	PIK3CG, KIT, SERPINA3, BMP6, CEBPB, CD40LG

Molecular functions related to myelodysplastic syndrome according to GeneDecks:

(show all 13)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:005515	14.0	MDM2, CCND1, CCNA1, GP1BA, IKBKB, IKBKG
2	sequence-specific DNA binding transcription factor activity	GO:003700	11.9	FOS, KLF11, KLF5, RB1, VDR, NFKB1
3	protein homodimerization activity	GO:042803	11.3	NPM1, MLL, RUNX1, CPQ, CSF1R, CSF1
4	chromatin binding	GO:003682	11.2	NCOA2, TGIF1, DNMT3A, NUP62, NSD1, RING1
5	receptor activity	GO:004872	11.2	ICAM1, TNFRSF6B, TEK, PLAUR, KLRG1, TLR4
6	transcription factor binding	GO:008134	11.1	CTNNB1, TMEM173, TNFRSF10A, MYC, TP53, CD34
7	protein kinase binding	GO:019901	10.8	CD226, CCNC, CDKN2A, CHEK2, AURKA, JAK2
8	vascular endothelial growth factor-activated receptor activity	GO:005021	10.7	PDGFRB, PDGFRA, FLT3, FLT4, FLT1, KDR
9	protein heterodimerization activity	GO:046982	10.6	IKBKB, TP53, BOK, TWIST1, TOP2A, TGFB1
10	identical protein binding	GO:042802	10.6	MDM2, FAS, IGF1R, AKT1, TRAF2, TRADD
11	enzyme binding	GO:019899	10.5	CTNNB1, PPARG, PLAUR, PLCB1, NFKBIA, ACSL6
12	cytokine activity	GO:005125	9.4	CSF2, IL7, FASLG, IFNA2, TNF, TNFSF10
13	growth factor activity	GO:008083	8.8	IL3, IL2, IL1B, IL11, FGF2, FGF1